Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

Genprex Inc. was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of SCLC.